Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type|Pathology location|Pathology Description|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-1|1|114|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-2|1|132|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-3|1|152|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-4|1|179|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-5|1|186|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-6|1|207|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-7|1|260|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-8|1|269|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-9|1|312|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-10|1|393|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-11|1|565|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-12|1|632|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-13|1|651|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-14|1|663|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-15|1|690|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-16|1|696|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-17|1|697|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-18|1|709|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-19|1|728|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-20|1|737|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-21|1|738|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-22|1|739|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-23|1|753|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-24|1|759|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ subcut. ventral in inguinal reg. Metastases  Skin tcfs of inguinal region infiltrates skin. Metastases  Muscle tcfs of inguinal region infiltrates muscle of thigh.,MPATH: 408 - soft tissue fibrosarcoma|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-25|1|760|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-26|1|761|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-27|1|763|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-28|1|764|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-29|1|770|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-30|1|774|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-31|1|775|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-32|1|787|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-33|1|788|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-34|1|805|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-35|1|808|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-36|1|809|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-37|1|814|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ in fatty tissue adjac. to one testis.|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-38|1|815|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-39|1|830|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-40|1|831|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-41|1|835|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ on capsule of left kidney.|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-42|1|837|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-43|1|838|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-44|1|846|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-45|1|848|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-46|1|850|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-47|1|858|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Eye(s) missing Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-48|1|864|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-49|1|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-50|1|865|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-51|1|866|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-52|1|866|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-53|1|868|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-54|1|869|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac growth on visc. pleura of lung. Metastases  Muscle trac infiltra. thoracic muscle.,MPATH: 268 - adenocarcinoma|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-55|1|871|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-56|1|876|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-57|1|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-58|1|881|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-59|1|881|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-60|1|886|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Heart,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-61|1|886|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-62|1|886|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-63|1|888|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-64|1|889|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-65|1|890|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-66|1|895|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-67|1|896|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-68|1|896|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-69|1|897|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-70|1|897|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-71|1|904|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-72|1|904|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-73|1|905|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-74|1|905|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-75|1|906|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-76|1|906|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-77|1|907|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-78|1|910|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-79|1|912|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-80|1|915|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-81|1|919|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-82|1|923|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-83|1|924|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-84|1|927|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-85|1|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-86|1|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-87|1|934|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-88|1|935|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to visc. perit.(spl., bladder neck,prost.) & visc. pleura (diaphragm & trachea). Metastases  Lymphoret.System trac to pt ln. Metastases Liver Metastases Heart Metastases  Muscle trac to muscle adjac. to ur. bl. & diaphragm.,MPATH: 268 - adenocarcinoma|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-89|1|936|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-90|1|937|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases Liver Metastases  trac to pleura of ht.,mediastinum, & lung.,MPATH: 268 - adenocarcinoma|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-91|1|938|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-92|1|938|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-93|1|939|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-94|1|941|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-95|1|941|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-96|1|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-97|1|951|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-98|1|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-99|1|958|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-100|1|958|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-101|1|965|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-102|1|970|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-103|1|976|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases Liver Metastases Kidney Metastases  Lymphoret.System trac to pt ln & bn.,MPATH: 268 - adenocarcinoma|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-104|1|980|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/   Metastases  trac to hard. gl.,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-105|1|981|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-106|1|981|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-107|1|983|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-108|1|984|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-109|1|985|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-110|1|985|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-111|1|997|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-112|1|998|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Skin tcfs of rt. chest area invades skin.,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-113|1|1000|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-114|1|1004|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ location not given-normal skeletal muscle & fat in section.|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-115|1|1008|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-116|1|1009|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-117|1|1010|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-118|1|1012|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-119|1|1014|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-120|1|1014|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-121|1|1015|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-122|1|1015|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-123|1|1020|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-124|1|1026|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-125|1|1029|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-126|1|1031|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-127|1|1032|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-128|1|1043|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-129|1|1047|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-130|1|1048|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-131|1|1050|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-132|1|1051|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-133|1|1052|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-134|1|1057|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-135|1|1059|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-136|1|1069|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-137|1|1069|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-138|1|1074|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-139|1|1074|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-140|1|1079|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-141|1|1093|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-142|1|1093|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-143|1|1099|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-144|1|1101|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-145|1|1107|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-146|1|1108|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-147|1|1120|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-148|1|1123|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-149|1|1124|Neoplasia malignant|Endocrine system|TGAC/   Metastases  Muscle tgac infiltr. muscle of head. Metastases Lung|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-150|1|1124|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-151|1|1125|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-152|1|1125|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-153|1|1126|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-154|1|1130|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to pt ln. Metastases  trac to pleura of lung & mediastinum.,MPATH: 268 - adenocarcinoma|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-155|1|1145|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-156|1|1145|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-157|1|1152|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-158|1|1153|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-159|1|1160|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-160|1|1160|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/   Metastases Lung|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-161|1|1169|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-162|1|1177|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-163|1|1191|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-164|1|1192|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-165|1|1194|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-166|1|1197|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-167|1|1197|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-168|1|1199|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-169|1|1199|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-170|1|1199|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/ 3 foci.,MPATH: 268 - adenocarcinoma|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-171|1|1203|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-172|1|1205|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-173|1|1210|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-174|1|1223|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-175|1|1224|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-176|1|1225|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-177|1|1226|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-178|1|1235|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-179|1|1240|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-180|1|1242|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to visc. pleura (ht base) & mediast. Metastases  Lymphoret.System trac to pt ln.,MPATH: 268 - adenocarcinoma|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-181|1|1247|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-182|1|1254|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-183|1|1256|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-184|1|1261|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-185|1|1262|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-186|1|1272|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-187|1|1272|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-188|1|1279|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-189|1|1279|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-190|1|1303|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-191|1|1311|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-192|1|1319|Other deterministic changes|Whole body|MCDU/|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-193|1|1320|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-194|1|1350|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-195|1|1352|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-196|1|1354|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-197|1|1394|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-198|1|1400|n/a|n/a|n/a|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-199|1|1423|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ subcut. right chest area. Metastases  Muscle tcfs of rt. chest area invades thor. muscle.,MPATH: 408 - soft tissue fibrosarcoma|
1003-23-1|n/a,LO|1|100|shamexposed|0|grays|External exposure|code L0 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|189 records survival 862 ± 15 lifespan study|1003-23-1-200|1|1497|Other deterministic changes|Whole body|MCDU/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-1|2|161|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-2|2|178|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-3|2|183|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-4|2|191|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-5|2|192|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-6|2|333|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-7|2|477|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-8|2|482|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-9|2|503|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-10|2|506|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-11|2|539|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-12|2|635|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-13|2|638|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-14|2|645|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-15|2|659|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-16|2|662|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-17|2|678|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-18|2|697|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-19|2|713|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-20|2|714|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-21|2|727|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-22|2|728|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-23|2|730|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-24|2|731|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-25|2|736|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-26|2|741|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-27|2|742|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/   Metastases Lung,MPATH: 242 - hemangiosarcoma|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-28|2|743|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ colon and cecum.Enteritis acute,MPATH: 212 - inflammation|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-29|2|749|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-30|2|752|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-31|2|756|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-32|2|762|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-33|2|768|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-34|2|771|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-35|2|771|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-36|2|773|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXEC/ urethra transitional cell carcinoma.,MPATH: 446 - squamous cell carcinoma|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-37|2|777|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-38|2|778|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-39|2|784|Neoplasia benign|Bloodvessels among cardiovascular system|TCVO/ thorax-left.|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-40|2|790|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-41|2|798|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-42|2|810|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-43|2|810|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-44|2|812|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-45|2|813|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-46|2|822|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-47|2|824|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-48|2|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-49|2|826|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-50|2|845|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-51|2|848|Other deterministic changes|Whole body|MCDU/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-52|2|848|Other deterministic changes|Whole body|MCDU/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-53|2|851|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-54|2|855|Other deterministic changes|Whole body|MCDU/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-55|2|856|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-56|2|856|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-57|2|858|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-58|2|863|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-59|2|866|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-60|2|868|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-61|2|868|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-62|2|869|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-63|2|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-64|2|874|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-65|2|879|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-66|2|879|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-67|2|887|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-68|2|887|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-69|2|888|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-70|2|888|Other deterministic changes|Whole body|MCDU/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-71|2|889|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-72|2|893|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXAC/ transitional cell type- carcinoma of urethra.,MPATH: 268 - adenocarcinoma|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-73|2|895|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-74|2|896|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-75|2|896|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-76|2|900|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-77|2|902|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-78|2|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-79|2|906|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ in connective tiss. in abd. cavity.|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-80|2|907|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-81|2|909|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-82|2|911|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-83|2|912|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-84|2|915|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-85|2|915|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-86|2|917|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Liver Metastases Heart Metastases Kidney,MPATH: 268 - adenocarcinoma|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-87|2|919|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-88|2|925|Other deterministic changes|Whole body|MCDU/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-89|2|926|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/  auricular|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-90|2|926|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-91|2|928|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-92|2|929|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-93|2|933|Other deterministic changes|Whole body|MCDU/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-94|2|935|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-95|2|939|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-96|2|941|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-97|2|941|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-98|2|953|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-99|2|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-100|2|955|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-101|2|962|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-102|2|964|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-103|2|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-104|2|969|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-105|2|971|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-106|2|974|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-107|2|977|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-108|2|977|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-109|2|981|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-110|2|981|Other deterministic changes|Whole body|MCDU/   Metastases  Muscle tgac to muscle adjac. to hard. gl.|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-111|2|985|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ adjac. to left side of lumbar spine.|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-112|2|985|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases  Muscle trac to muscle of back between forelimbs.,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-113|2|988|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-114|2|995|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-115|2|995|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-116|2|1003|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-117|2|1005|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-118|2|1006|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVO/  ,MPATH: 235 - blood vessel tumor|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-119|2|1008|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-120|2|1008|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-121|2|1011|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-122|2|1016|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-123|2|1017|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-124|2|1022|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-125|2|1022|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-126|2|1023|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-127|2|1031|Other deterministic changes|Whole body|MCDU/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-128|2|1032|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-129|2|1035|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-130|2|1036|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-131|2|1036|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-132|2|1038|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-133|2|1038|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-134|2|1038|Other deterministic changes|Whole body|MCDU/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-135|2|1042|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ dorsal - along spine in lumbar region.|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-136|2|1045|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-137|2|1054|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-138|2|1055|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-139|2|1058|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-140|2|1059|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-141|2|1061|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-142|2|1064|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-143|2|1068|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-144|2|1069|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ dorsal thoracic region. Metastases  Muscle tcvs invading muscle.|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-145|2|1072|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-146|2|1073|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-147|2|1074|Other deterministic changes|Whole body|MCDU/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-148|2|1075|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-149|2|1077|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-150|2|1078|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-151|2|1079|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to pleura of lung.,MPATH: 268 - adenocarcinoma|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-152|2|1079|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-153|2|1079|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-154|2|1082|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-155|2|1083|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-156|2|1091|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-157|2|1092|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-158|2|1095|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-159|2|1098|Other deterministic changes|Whole body|MCDU/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-160|2|1103|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-161|2|1109|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-162|2|1114|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-163|2|1114|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-164|2|1116|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-165|2|1121|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-166|2|1124|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-167|2|1126|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-168|2|1127|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-169|2|1132|Other deterministic changes|Whole body|MCDU/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-170|2|1134|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Kidney tvss embolus in renal vein.,MPATH: 268 - adenocarcinoma|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-171|2|1136|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-172|2|1140|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-173|2|1144|Other deterministic changes|Whole body|MCDU/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-174|2|1160|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-175|2|1163|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-176|2|1170|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-177|2|1173|Other deterministic changes|Whole body|MCDU/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-178|2|1174|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-179|2|1180|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-180|2|1180|Other deterministic changes|Whole body|MCDU/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-181|2|1184|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-182|2|1192|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-183|2|1207|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-184|2|1208|Other deterministic changes|Whole body|MCDU/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-185|2|1223|Other deterministic changes|Whole body|MCDU/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-186|2|1225|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-187|2|1226|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-188|2|1228|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-189|2|1233|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-190|2|1234|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-191|2|1238|Other deterministic changes|Whole body|MCDU/|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-192|2|1240|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-193|2|1257|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/   Metastases  tkac growth on visc. perit.- kidney capsule.,MPATH: 549 - carcinoma|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-194|2|1265|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-195|2|1272|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases Lung Metastases  Muscle tcvs infilt. muscle of esoph.,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-196|2|1299|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-197|2|1323|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/  chronic hepatitis,MPATH: 212 - inflammation|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-198|2|1339|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-199|2|1345|n/a|n/a|n/a|
1003-23-2|n/a,L1|1|100|gamma-rays Co-60|2.06|grays|External exposure|code L1 5 fractions 1320 m 5/w|200 (200 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|194 records survival 830 ± 13 lifespan study|1003-23-2-200|2|1393|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-1|3|171|Other deterministic changes|Whole body|MCDU/|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-2|3|186|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-3|3|276|Other deterministic changes|Whole body|MCDU/|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-4|3|558|Neoplasia malignant|Bloodvessels among cardiovascular system|TTVS/  Testis|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-5|3|561|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-6|3|565|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-7|3|578|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-8|3|589|Other deterministic changes|Whole body|MCDU/|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-9|3|610|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-10|3|629|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-11|3|635|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-12|3|635|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-13|3|649|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-14|3|657|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-15|3|663|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-16|3|680|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-17|3|682|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-18|3|698|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-19|3|729|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-20|3|730|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-21|3|741|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-22|3|744|Other deterministic changes|Whole body|MCDU/|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-23|3|779|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-24|3|782|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ right neck.|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-25|3|795|Other deterministic changes|Whole body|MCDU/|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-26|3|801|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-27|3|818|Other deterministic changes|Whole body|MCDU/|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-28|3|822|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-29|3|826|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-30|3|842|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-31|3|851|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-32|3|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-33|3|854|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-34|3|858|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-35|3|873|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-36|3|896|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ on peritoneal wall. Metastases  Muscle tcvs infilt. muscle of peritoneal wall.|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-37|3|908|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-38|3|918|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-39|3|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-40|3|926|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-41|3|928|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-42|3|932|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-43|3|932|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-44|3|936|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-45|3|948|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-46|3|948|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  Head/neck missing Eye(s) missing,MPATH: 242 - hemangiosarcoma|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-47|3|957|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-48|3|962|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-49|3|966|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-50|3|967|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-51|3|971|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-52|3|973|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-53|3|974|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-54|3|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-55|3|978|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-56|3|979|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-57|3|980|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-58|3|987|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-59|3|993|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-60|3|1011|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-61|3|1011|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-62|3|1012|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-63|3|1012|Neoplasia systemic|Haematolymphatic system|TLML/  Head/neck missing|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-64|3|1018|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to thoracic muscle. Metastases  trac to pleura of lung & mediastinum.Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-65|3|1029|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-66|3|1032|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-67|3|1034|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-68|3|1037|Other deterministic changes|Whole body|MCDU/|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-69|3|1043|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-70|3|1050|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-71|3|1050|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-72|3|1051|Other deterministic changes|Whole body|MCDU/|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-73|3|1053|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-74|3|1055|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-75|3|1063|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-76|3|1063|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-77|3|1069|Other deterministic changes|Whole body|MCDU/   Metastases  Lymphoret.System trac to pt ln.|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-78|3|1075|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-79|3|1086|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-80|3|1109|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-81|3|1119|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXUO/ salivary gland-myoepithelioma.,MPATH: 218 - neoplasm|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-82|3|1125|Other deterministic changes|Whole body|MCDU/|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-83|3|1134|Other deterministic changes|Whole body|MCDU/|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-84|3|1136|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-85|3|1140|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-86|3|1151|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-87|3|1154|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-88|3|1175|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-89|3|1179|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-90|3|1182|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-91|3|1212|Other deterministic changes|Whole body|MCDU/|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-92|3|1230|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-93|3|1237|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-94|3|1243|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-95|3|1258|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-96|3|1267|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-97|3|1298|Changes due to an abnormal circulation|Bloodvessels among cardiovascular system|MTHR/  auricular|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-98|3|1331|n/a|n/a|n/a|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-99|3|1333|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-23-3|n/a,L2|1|100|gamma-rays Co-60|4.17|grays|External exposure|code L2 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 806 ± 22 lifespan study|1003-23-3-100|3|1346|Other deterministic changes|Whole body|MCDU/|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-1|4|154|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-2|4|157|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-3|4|157|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-4|4|261|Other deterministic changes|Whole body|MCDU/|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-5|4|282|Other deterministic changes|Whole body|MCDU/|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-6|4|284|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-7|4|303|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-8|4|437|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-9|4|488|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-10|4|510|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-11|4|529|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-12|4|546|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-13|4|582|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-14|4|589|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-15|4|600|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-16|4|601|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-17|4|656|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-18|4|666|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-19|4|675|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-20|4|676|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-21|4|684|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-22|4|693|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-23|4|695|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-24|4|701|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-25|4|709|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-26|4|722|Other deterministic changes|Whole body|MCDU/|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-27|4|724|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-28|4|725|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-29|4|729|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-30|4|732|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-31|4|734|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-32|4|743|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-33|4|744|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-34|4|747|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-35|4|761|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-36|4|764|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-37|4|775|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-38|4|779|Other deterministic changes|Whole body|MCDU/|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-39|4|780|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-40|4|790|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-41|4|792|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-42|4|806|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-43|4|828|Other deterministic changes|Whole body|MCDU/|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-44|4|830|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-45|4|833|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-46|4|834|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-47|4|839|Other deterministic changes|Whole body|MCDU/|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-48|4|845|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-49|4|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-50|4|869|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-51|4|875|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-52|4|881|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-53|4|891|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-54|4|903|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-55|4|908|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-56|4|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-57|4|919|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-58|4|932|Other deterministic changes|Whole body|MCDU/|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-59|4|937|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-60|4|937|Other deterministic changes|Whole body|MCDU/  Thorax missing Eye(s) missing Head/neck missing|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-61|4|938|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-62|4|945|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-63|4|946|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-64|4|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-65|4|954|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-66|4|973|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-67|4|980|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-68|4|980|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-69|4|989|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-70|4|1002|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-71|4|1023|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-72|4|1024|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-73|4|1053|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-74|4|1077|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-75|4|1080|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-76|4|1094|Inflammation and/or fibrotic diseases|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|MHIC/  chronic hepatitis,MPATH: 212 - inflammation|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-77|4|1107|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-78|4|1109|n/a|n/a|n/a|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-79|4|1145|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-23-4|n/a,L3|1|100|gamma-rays Co-60|9.59|grays|External exposure|code L3 5 fractions 1320 m 5/w|80 (80 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|76 records survival 675 ± 23 lifespan study|1003-23-4-80|4|1165|n/a|n/a|n/a|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-1|5|185|Other deterministic changes|Whole body|MCDU/|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-2|5|297|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-3|5|337|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-4|5|374|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-5|5|386|n/a|n/a|n/a|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-6|5|449|Other deterministic changes|Whole body|MCDU/|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-7|5|498|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-8|5|504|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-9|5|575|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-10|5|584|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-11|5|604|Other deterministic changes|Whole body|MCDU/|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-12|5|604|n/a|n/a|n/a|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-13|5|652|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-14|5|659|n/a|n/a|n/a|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-15|5|666|Other deterministic changes|Whole body|MCDU/|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-16|5|691|n/a|n/a|n/a|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-17|5|692|Other deterministic changes|Whole body|MCDU/|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-18|5|699|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-19|5|748|Other deterministic changes|Whole body|MCDU/|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-20|5|750|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-21|5|751|n/a|n/a|n/a|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-22|5|771|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-23|5|780|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-24|5|780|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-25|5|792|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/   Metastases  Muscle tcvs infiltrates muscle.,MPATH: 242 - hemangiosarcoma|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-26|5|800|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  Skin tcvs infiltrat. skin.,MPATH: 513 - Lymphoid neoplasms|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-27|5|801|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-28|5|802|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-29|5|830|Other deterministic changes|Whole body|MCDU/  Head/neck missing|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-30|5|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-31|5|867|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-32|5|876|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-33|5|877|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-34|5|882|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|TKAC/  ,MPATH: 549 - carcinoma|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-35|5|952|n/a|n/a|n/a|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-36|5|956|n/a|n/a|n/a|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-37|5|969|n/a|n/a|n/a|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-38|5|991|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-39|5|994|n/a|n/a|n/a|
1003-23-5|n/a,L4|1|100|gamma-rays Co-60|19.18|grays|External exposure|code L4 5 fractions 1320 m 5/w|40 (40 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|40 records survival 578 ± 32 lifespan study|1003-23-5-40|5|1065|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-1|6|192|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-2|6|203|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-3|6|227|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-4|6|320|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-5|6|332|Other deterministic changes|Whole body|MCDU/|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-6|6|341|Other deterministic changes|Whole body|MCDU/|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-7|6|392|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-8|6|448|Other deterministic changes|Whole body|MCDU/|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-9|6|486|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-10|6|493|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-11|6|511|Other deterministic changes|Whole body|MCDU/|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-12|6|532|Other deterministic changes|Whole body|MCDU/|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-13|6|537|Other deterministic changes|Whole body|MCDU/|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-14|6|583|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-15|6|609|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-16|6|648|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-17|6|649|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-18|6|654|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-19|6|664|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-20|6|680|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-21|6|682|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-22|6|702|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-23|6|714|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-24|6|716|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-25|6|725|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-26|6|726|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-27|6|738|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-28|6|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-29|6|745|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-30|6|749|Other deterministic changes|Whole body|MCDU/|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-31|6|760|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-32|6|760|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-33|6|762|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-34|6|763|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-35|6|766|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-36|6|771|Neoplasia malignant|Liver among hepato-pancreatic system diseases|THAC/|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-37|6|772|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-38|6|774|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-39|6|775|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-40|6|777|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-41|6|789|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-42|6|793|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-43|6|794|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to thigh muscle. Metastases Heart,MPATH: 268 - adenocarcinoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-44|6|796|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-45|6|800|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-46|6|802|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-47|6|806|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-48|6|818|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-49|6|818|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Muscle trac to muscle of ribs. Metastases  trac to visc. pleura & parietal pleura.Head/neck missing Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-50|6|819|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-51|6|832|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-52|6|834|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-53|6|839|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-54|6|851|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-55|6|852|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-56|6|854|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-57|6|857|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-58|6|858|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-59|6|862|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-60|6|865|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-61|6|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-62|6|871|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases Kidney,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-63|6|879|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-64|6|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-65|6|884|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-66|6|888|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-67|6|889|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-68|6|889|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-69|6|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-70|6|895|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-71|6|896|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-72|6|902|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-73|6|902|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-74|6|905|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-75|6|910|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-76|6|912|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-77|6|913|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-78|6|914|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-79|6|915|Inflammation and/or fibrotic diseases|Cardiovascular system,MA: 0000099 - pericardium|MPCA/  acute,MPATH: 212 - inflammation|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-80|6|917|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-81|6|918|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-82|6|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-83|6|925|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-84|6|929|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-85|6|929|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-86|6|932|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-87|6|935|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-88|6|939|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosaHead/neck missing Thorax missing Eye(s) missing|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-89|6|942|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-90|6|947|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-91|6|952|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-92|6|965|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-93|6|968|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-94|6|968|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-95|6|969|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-96|6|978|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-97|6|983|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-98|6|987|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-99|6|992|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-100|6|993|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-101|6|999|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-102|6|1000|Other deterministic changes|Whole body|MCDU/|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-103|6|1000|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-104|6|1001|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVO/  ,MPATH: 235 - blood vessel tumor|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-105|6|1006|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-106|6|1007|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ dorsal on thorax & upper lumbar reg. Metastases  Muscle tcfs of thorax invad. muscle.,MPATH: 408 - soft tissue fibrosarcoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-107|6|1008|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-108|6|1009|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-109|6|1009|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-110|6|1011|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-111|6|1011|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-112|6|1016|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVO/  Head/neck missing Eye(s) missing,MPATH: 235 - blood vessel tumor|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-113|6|1017|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-114|6|1017|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-115|6|1018|Other deterministic changes|Whole body|MCDU/  Thorax missing Eye(s) missing Head/neck missing|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-116|6|1021|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-117|6|1029|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-118|6|1031|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-119|6|1032|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac metast. to pt. & mediastinum.,MPATH: 268 - adenocarcinoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-120|6|1038|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-121|6|1042|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-122|6|1045|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac metast. to pleura of lung & mediastinum. Metastases  trac growth on pleura of lung & on esophagus.,MPATH: 268 - adenocarcinoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-123|6|1050|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-124|6|1054|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-125|6|1057|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-126|6|1065|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-127|6|1071|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-128|6|1072|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-129|6|1074|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXEC/ adjacent to sem. ves.,MPATH: 446 - squamous cell carcinoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-130|6|1079|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-131|6|1080|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-132|6|1083|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-133|6|1087|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-134|6|1091|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-135|6|1094|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Eye(s) missing,MPATH: 242 - hemangiosarcoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-136|6|1096|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-137|6|1103|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-138|6|1105|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-139|6|1109|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-140|6|1110|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-141|6|1112|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-142|6|1113|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-143|6|1115|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-144|6|1115|Other deterministic changes|Whole body|MCDU/|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-145|6|1124|Other deterministic changes|Whole body|MCDU/|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-146|6|1125|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-147|6|1129|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-148|6|1131|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-149|6|1139|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-150|6|1148|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus|MSVA/ ac. supp. inflamm. of urethra, prostate, and seminal vesicle.Seminal vesicles|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-151|6|1158|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-152|6|1159|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ colon.Enteritis acute,MPATH: 212 - inflammation|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-153|6|1160|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-154|6|1165|Inflammation and/or fibrotic diseases|Lower digestive tract,MA: 0000328 - intestine|MIIA/ rectum.Enteritis acute,MPATH: 212 - inflammation|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-155|6|1174|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  Eye(s) missing,MPATH: 242 - hemangiosarcoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-156|6|1176|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-157|6|1177|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-158|6|1184|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-159|6|1186|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-160|6|1196|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-161|6|1198|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-162|6|1198|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBCS/ lower right hind leg & foot. Metastases  Muscle tbcs invas. of skel. muscle of leg and foot.|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-163|6|1199|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-164|6|1199|Other deterministic changes|Whole body|MCDU/|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-165|6|1201|Other deterministic changes|Whole body|MCDU/|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-166|6|1201|Other deterministic changes|Whole body|MCDU/  Eye(s) missing|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-167|6|1212|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-168|6|1218|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ subcut. on back. Metastases Lung Metastases  tcfs of back metast. in visc. perit. Metastases  Skin tcfs of back infilt. of skin on back. Metastases  Muscle tcfs of back infilt. of muscle on back.,MPATH: 408 - soft tissue fibrosarcoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-169|6|1234|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-170|6|1235|Other deterministic changes|Whole body|MCDU/|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-171|6|1238|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-172|6|1248|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ subcut. dorsal. Metastases  Muscle tcfs of back invades underlying muscle. Metastases  Skin tcfs of back invades skin.,MPATH: 408 - soft tissue fibrosarcoma|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-173|6|1273|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-174|6|1275|n/a|n/a|n/a|
1003-23-6|n/a,LG|1|100|shamexposed|0|grays|External exposure|code LC 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|173 records survival 803 ± 16 lifespan study|1003-23-6-175|6|1302|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-1|7|132|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-2|7|152|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-3|7|180|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-4|7|187|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-5|7|241|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-6|7|264|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-7|7|332|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-8|7|357|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-9|7|411|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-10|7|437|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-11|7|455|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-12|7|460|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-13|7|585|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-14|7|589|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-15|7|590|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-16|7|592|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-17|7|594|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-18|7|634|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-19|7|652|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-20|7|686|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-21|7|688|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-22|7|692|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-23|7|697|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-24|7|704|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-25|7|706|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to visc. & parietal pleura and pariet. perit. Metastases  Lymphoret.System trac to mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-26|7|719|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-27|7|720|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-28|7|725|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-29|7|728|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-30|7|729|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-31|7|729|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-32|7|732|Neoplasia malignant|Bone among musculo-skeletal system diseases|TBOS/ scapula. Metastases  Muscle tbos (scapula) to adj. muscle.|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-33|7|741|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-34|7|742|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Heart Metastases Kidney Metastases  Lymphoret.System trac to pt ln.,MPATH: 268 - adenocarcinoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-35|7|752|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-36|7|755|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-37|7|760|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-38|7|761|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-39|7|762|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-40|7|762|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-41|7|769|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-42|7|771|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-43|7|775|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-44|7|776|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-45|7|777|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing Thorax missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-46|7|784|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-47|7|789|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to pt ln.,MPATH: 268 - adenocarcinoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-48|7|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-49|7|803|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/   Metastases  trac to pleura of ht. base & lung.,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-50|7|806|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-51|7|807|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-52|7|807|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-53|7|807|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-54|7|808|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-55|7|809|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-56|7|823|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ at base of tail & extends into rt. thigh. Metastases  Muscle tcvs infilt. muscle of thigh & tail.|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-57|7|823|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-58|7|825|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-59|7|828|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-60|7|829|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-61|7|832|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-62|7|837|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-63|7|839|Neoplasia systemic|Haematolymphatic system|TLML/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-64|7|845|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-65|7|845|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-66|7|845|Other deterministic changes|Whole body|MCDU/  Head/neck missing|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-67|7|847|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-68|7|849|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-69|7|852|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-70|7|857|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-71|7|857|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-72|7|864|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-73|7|864|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-74|7|871|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-75|7|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-76|7|878|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-77|7|878|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-78|7|879|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  Head/neck missing Thorax missing Eye(s) missing,MPATH: 242 - hemangiosarcoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-79|7|880|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ in area of testis,sem. ves., etc.Head/neck missing Eye(s) missing|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-80|7|884|Neoplasia malignant|Endocrine system|TGAC/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-81|7|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-82|7|887|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVO/  ,MPATH: 240 - hemangioma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-83|7|891|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-84|7|892|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ surrounding male accessory organs.|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-85|7|892|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-86|7|893|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-87|7|909|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-88|7|911|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ around base of tail. Metastases  Muscle tcvs invas. of muscle at base of tail.|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-89|7|911|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to lung pleura.,MPATH: 268 - adenocarcinoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-90|7|912|Other deterministic changes|Whole body|MCDU/  Head/neck missing Eye(s) missing|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-91|7|912|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-92|7|912|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-93|7|914|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-94|7|917|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/   Metastases  Muscle tcvs invas. of muscle of leg & along spine.Eye(s) missing Head/neck missing,MPATH: 242 - hemangiosarcoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-95|7|917|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-96|7|923|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-97|7|924|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-98|7|926|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-99|7|927|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-100|7|927|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ right leg. Metastases  Muscle tcvs of leg invades muscle.|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-101|7|936|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-102|7|949|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-103|7|955|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-104|7|955|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-105|7|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-106|7|958|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-107|7|958|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-108|7|960|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-109|7|961|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-110|7|962|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-111|7|962|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-112|7|964|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-113|7|965|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-114|7|965|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-115|7|966|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-116|7|967|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-117|7|968|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ right external ear.,MPATH: 218 - neoplasm|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-118|7|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-119|7|970|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-120|7|970|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-121|7|971|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-122|7|973|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-123|7|973|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-124|7|973|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-125|7|975|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-126|7|976|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-127|7|988|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-128|7|990|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-129|7|992|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-130|7|995|Neoplasia malignant|Bloodvessels among cardiovascular system|TBVS/ left knee. Metastases  Muscle tbvs invas. of knee muscle.|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-131|7|995|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-132|7|1000|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-133|7|1010|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-134|7|1011|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-135|7|1014|Hyperplastic changes|Cardiovascular system|MPAN/  Polyarteritis nodosa|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-136|7|1021|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-137|7|1024|Other deterministic changes|Whole body|MCDU/  Eye(s) missing|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-138|7|1025|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-139|7|1026|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-140|7|1026|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVO/  ,MPATH: 235 - blood vessel tumor|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-141|7|1036|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|MRMP/  Murine Metastases  Muscle trac to muscle of femur & tibia.,MPATH: 212 - inflammation|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-142|7|1038|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-143|7|1040|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-144|7|1046|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  trac to pleura of lung. Metastases  Lymphoret.System trac in pt ln.,MPATH: 268 - adenocarcinoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-145|7|1052|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-146|7|1053|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-147|7|1057|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-148|7|1062|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-149|7|1063|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-150|7|1082|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-151|7|1083|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-152|7|1086|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-153|7|1103|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-154|7|1112|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-155|7|1114|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-156|7|1120|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-157|7|1122|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-158|7|1127|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-159|7|1133|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-160|7|1136|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/   Metastases  Muscle trac to costal muscles.,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-161|7|1140|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-162|7|1144|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-163|7|1163|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVO/  ,MPATH: 235 - blood vessel tumor|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-164|7|1175|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-165|7|1179|n/a|n/a|n/a|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-166|7|1196|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-167|7|1197|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-168|7|1203|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-169|7|1206|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-170|7|1218|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  trac on pleura of lung & base of heart & trachea.,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-171|7|1222|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-172|7|1250|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-173|7|1256|Other deterministic changes|Whole body|MCDU/|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-174|7|1260|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-7|n/a,L5|1|100|gamma-rays Co-60|5.29|grays|External exposure|code L5 5 fractions 1320 m 5/w|175 (175 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|170 records survival 767 ± 15 lifespan study|1003-23-7-175|7|1308|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-1|8|323|Other deterministic changes|Whole body|MCDU/|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-2|8|338|Other deterministic changes|Whole body|MCDU/|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-3|8|461|Other deterministic changes|Whole body|MCDU/|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-4|8|488|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-5|8|516|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-6|8|531|Other deterministic changes|Whole body|MCDU/|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-7|8|538|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-8|8|597|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-9|8|627|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ 2 sites-right thigh muscle and mesentery around stomach.Eye(s) missing|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-10|8|629|Neoplasia malignant|Bloodvessels among cardiovascular system|TMVS/ subcut. at base of spine. Muscle|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-11|8|652|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-12|8|669|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-13|8|696|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases Lung Metastases  Lymphoret.System trac to pt ln & mediastinal ln.,MPATH: 268 - adenocarcinoma|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-14|8|712|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-15|8|724|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-16|8|731|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-17|8|735|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ subcut. left thorax.|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-18|8|736|Degenerative changes|Kidney among urinary system diseases,MA: 0000368 - kidney|MCRD/  ,MPATH: 1 - cell and tissue damage|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-19|8|744|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-20|8|744|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-21|8|747|Other deterministic changes|Whole body|MCDU/|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-22|8|751|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  Head/neck missing,MPATH: 242 - hemangiosarcoma|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-23|8|754|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-24|8|758|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-25|8|762|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-26|8|762|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-27|8|768|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TXEC/ transitional cell carcinoma of urethra.,MPATH: 446 - squamous cell carcinoma|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-28|8|770|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-29|8|776|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-30|8|779|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-31|8|782|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-32|8|787|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-33|8|791|Other deterministic changes|Whole body|MCDU/  Head/neck missing|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-34|8|801|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-35|8|806|Other deterministic changes|Whole body|MCDU/|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-36|8|807|Neoplasia benign|Bloodvessels among cardiovascular system|TCVO/ subcut. left abd. quadrant.Head/neck missing|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-37|8|813|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-38|8|815|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-39|8|815|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-40|8|830|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-41|8|833|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Thorax missing Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-42|8|833|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-43|8|835|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-44|8|835|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-45|8|838|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-46|8|841|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVO/   Metastases  trac to visc. perit. of lung ,heart base & mediast. & parietal pleura of rib cage.,MPATH: 235 - blood vessel tumor|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-47|8|842|Other deterministic changes|Whole body|MCDU/  Thorax missing Eye(s) missing Head/neck missing|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-48|8|845|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-49|8|846|Other deterministic changes|Whole body|MCDU/|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-50|8|849|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Eye(s) missing Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-51|8|851|Neoplasia malignant|Bloodvessels among cardiovascular system|TSVS/ right forelimb.Skin|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-52|8|854|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-53|8|855|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-54|8|855|Other deterministic changes|Whole body|MCDU/  Eye(s) missing Thorax missing Head/neck missing|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-55|8|862|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-56|8|865|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-57|8|873|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System trac to pt ln. Metastases  Muscle trac to muscles of ribs. Metastases  trac to visc. pleura of lung & ht. base.,MPATH: 268 - adenocarcinoma|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-58|8|880|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart Metastases LiverHead/neck missing|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-59|8|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-60|8|887|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-61|8|888|Other deterministic changes|Whole body|MCDU/  Head/neck missing Thorax missing Eye(s) missing|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-62|8|891|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-63|8|894|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-64|8|896|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-65|8|899|Other deterministic changes|Whole body|MCDU/  Head/neck missing Eye(s) missing|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-66|8|901|Other deterministic changes|Whole body|MCDU/  Head/neck missing Eye(s) missing|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-67|8|902|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart Metastases Lung|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-68|8|908|Other deterministic changes|Whole body|MCDU/|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-69|8|912|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-70|8|916|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-71|8|919|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing Eye(s) missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-72|8|920|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-73|8|921|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-74|8|922|Other deterministic changes|Whole body|MCDU/|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-75|8|934|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-76|8|941|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-77|8|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-78|8|953|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-79|8|955|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-80|8|957|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-81|8|961|Other deterministic changes|Whole body|MCDU/|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-82|8|962|n/a|n/a|n/a|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-83|8|963|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-84|8|967|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-85|8|974|Neoplasia unclassified|Integumentary system,MA: 0000151 - skin|TSEC/ on skull & jaw bone. Metastases  Muscle tsec invas. of muscles of skull & jaw bone.,MPATH: 218 - neoplasm|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-86|8|980|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|TCFS/ left axillary region. Metastases  Muscle tcfs infilt. muscle & bone (rib). Metastases  Skin tcfs infilt. skin.,MPATH: 408 - soft tissue fibrosarcoma|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-87|8|994|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-88|8|1004|Other deterministic changes|Whole body|MCDU/  Eye(s) missing|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-89|8|1006|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLHS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-90|8|1020|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-91|8|1046|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-92|8|1046|Other deterministic changes|Whole body|MCDU/|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-93|8|1064|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-94|8|1085|Other deterministic changes|Whole body|MCDU/|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-95|8|1099|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-96|8|1105|Other deterministic changes|Whole body|MCDU/|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-97|8|1119|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-98|8|1121|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-99|8|1124|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-8|n/a,L6|1|100|gamma-rays Co-60|10.7|grays|External exposure|code L6 5 fractions 1320 m 5/w|100 (100 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|99 records survival 719 ± 16 lifespan study|1003-23-8-100|8|1162|Other deterministic changes|Whole body|MCDU/|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-1|9|143|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-2|9|178|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-3|9|235|Other deterministic changes|Whole body|MCDU/|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-4|9|301|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-5|9|388|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-6|9|444|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-7|9|482|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-8|9|488|Neoplasia malignant|Bloodvessels among cardiovascular system|TIVS/ jejunum.|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-9|9|496|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-10|9|546|Other deterministic changes|Whole body|MCDU/|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-11|9|564|Neoplasia unclassified|Central nervous system among nervous system|TNXS/ brain-cerebrum; not mixed cell type.|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-12|9|570|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-13|9|574|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-14|9|575|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-15|9|593|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-16|9|601|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|THVS/  ,MPATH: 242 - hemangiosarcoma|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-17|9|622|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-18|9|624|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-19|9|632|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-20|9|638|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-21|9|643|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-22|9|645|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-23|9|648|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-24|9|652|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-25|9|659|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-26|9|667|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-27|9|671|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-28|9|671|Other deterministic changes|Whole body|MCDU/  Eye(s) missing|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-29|9|676|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-30|9|695|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-31|9|699|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-32|9|702|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLXS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-33|9|727|Neoplasia unclassified|Lower digestive tract,MA: 0000328 - intestine|TIAC/ pylorus. Metastases Lung,MPATH: 218 - neoplasm|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-34|9|733|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/   Metastases  Lymphoret.System thac metast. to mediast. ln. & neck ln. Metastases  Muscle trac to costal musc. of ribs & sternum. Metastases  trac metast. in visc. pleura & on parietal pleura. Metastases  Lymphoret.System trac to mediast. ln.,MPATH: 268 - adenocarcinoma|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-35|9|734|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-36|9|737|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ left leg.|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-37|9|738|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Eye(s) missing Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-38|9|749|Other deterministic changes|Whole body|MCDU/|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-39|9|762|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-40|9|772|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-41|9|776|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-42|9|783|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-43|9|786|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Eye(s) missing,MPATH: 268 - adenocarcinoma|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-44|9|807|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-45|9|810|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-46|9|812|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  Head/neck missing,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-47|9|814|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-48|9|816|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-49|9|822|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-50|9|827|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Eye(s) missing Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-51|9|829|Other deterministic changes|Whole body|MCDU/|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-52|9|836|Neoplasia malignant|Bloodvessels among cardiovascular system|TYVS/  Heart|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-53|9|836|Other deterministic changes|Whole body|MCDU/|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-54|9|847|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLL/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-55|9|851|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-56|9|858|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|TNMS/   Metastases  Muscle tnms invades muscles of skull & of orbit.,MPATH: 551 - sarcoma|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-57|9|867|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ base of tail. Metastases  Muscle tcvs invades muscle & bone of tail and pelvis.|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-58|9|870|Other deterministic changes|Whole body|MCDU/|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-59|9|872|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-60|9|882|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-61|9|887|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-62|9|889|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  Head/neck missing,MPATH: 268 - adenocarcinoma|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-63|9|897|Neoplasia malignant|Bloodvessels among cardiovascular system|TCVS/ right leg.|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-64|9|903|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-65|9|922|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/   Metastases  trac to pleura of esoph. & lung.,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-66|9|928|Other deterministic changes|Whole body|MCDU/|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-67|9|947|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-68|9|957|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-69|9|966|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-70|9|967|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLLS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-71|9|977|n/a|n/a|n/a|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-72|9|997|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-73|9|1001|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|TLUS/  ,MPATH: 513 - Lymphoid neoplasms|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-74|9|1021|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|TRAC/  ,MPATH: 268 - adenocarcinoma|
1003-23-9|n/a,L7|1|100|gamma-rays Co-60|24.6|grays|External exposure|code L7 5 fractions 1320 m 5/w|75 (75 in ERA)|Mouse|Mouse, B6CF1|Male|Juvenile|74 records survival 608 ± 22 lifespan study|1003-23-9-75|9|1070|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|TEVS/  ,MPATH: 242 - hemangiosarcoma|
